Clinical Utility of Preoperative Vitamin D3 Injection for Preventing Transient Hypocalcemia after Total Thyroidectomy
Table 1
Comparison of baseline clinicopathologic characteristics between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN) groups.
VDI (n = 342)
VDN (n = 1952)
value
Age (years)
44.3 ± 13.0 (range, 12–81)
45.8 ± 13.7 (range, 8–84)
0.051
Female
253 (74.0%)
1493 (76.5%)
0.336
Multifocality
193 (56.4%)
1114 (57.1%)
0.859
Bilaterality
167 (48.8%)
894 (45.8%)
0.410
ETE
61 (17.8%)
308 (15.8%)
0.339
Operation time (min)
149.8 ± 78.7 (range, 48–835)
150.1 ± 75.6 (range, 50–635)
0.946
Hospital stay (day)
4.0 ± 1.8 (range, 2–17)
3.9 ± 1.7 (range, 2–37)
0.074
Tumor size (cm)
1.4 ± 1.0 (range, 0.2–6.3)
1.3 ± 0.9 (range, 0.2–10.5)
0.259
T stage
0.184
T1
249 (72.8%)
1466 (75.1%)
T2
32 (9.4%)
169 (8.7%)
T3
9 (2.6%)
97 (5.0%)
T4a
52 (15.2%)
213 (10.9%)
T4b
0 (0%)
4 (0.2%)
N stage
0.082
N0
113 (33.0%)
667 (34.2%)
N1a
101 (29.5%)
693 (35.5%)
N1b
128 (37.5%)
592 (30.3%)
M stage
0.156
M1
6 (1.8%)
18 (0.9%)
TNM stage
0.530
Stage I
287 (83.9%)
1597 (81.8%)
Stage II
39 (11.4%)
278 (14.2%)
Stage III
15 (4.4%)
65 (3.3%)
Stage IVa
0 (0%)
2 (0.1%)
Stage IVb
1 (0.3%)
7 (0.4%)
Transient hypocalcemia
67 (19.6%)
571 (29.3%)
<0.001
Data are expressed as patient’s number (%), or mean ± SD. A statistically significant difference was defined as < 0.05. ETE, extrathyroidal extension; T, tumor; N, node; M, metastasis.
